Verastem doses first patient in Phase 2 TARGET-D 203 trial of KRAS G12D inhibitor VS-7375 in metastatic colorectal cancer

• Verastem dosed the first patient in TARGET-D 203, a Phase 2 registration-directed trial of VS-7375 for KRAS G12D-mutated metastatic colorectal cancer.
• The study tests VS-7375 alone or with EGFR blockade; it also explores a first-line regimen combining VS-7375 with cetuximab, chemotherapy.
• Early findings from an ongoing Phase 1/2 program have already been presented, showing preliminary anti-tumor activity with manageable safety in monotherapy, combination cohorts.
• An additional clinical update is expected in the second half of 2026, extending the company’s KRAS G12D development push across colorectal, pancreatic, lung cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260728067241) on July 28, 2026, and is solely responsible for the information contained therein.